J M S Bartlett
Overview
Explore the profile of J M S Bartlett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
1818
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Crozier C, Wood G, Foster R, Stasi S, Liu J, Bartlett J, et al.
J Comp Pathol
. 2016 Jun;
155(1):24-8.
PMID: 27290644
Companion animals may serve as valuable models for studying human cancers. Although KRAS is the most commonly mutated gene in human ductal pancreatic cancers (57%), with mutations frequently occurring at...
12.
Bartlett J, Nielsen T, Gao D, Gelmon K, Quintayo M, Starczynski J, et al.
Br J Cancer
. 2015 Aug;
113(5):722-8.
PMID: 26284338
Background: TLE3, a nuclear transcriptional repressor downstream of WNT signalling pathways, has been hypothesised as predictive of benefit from adjuvant taxane. Methods: MA.21 tissue microarrays were constructed from 1097 out...
13.
Speirs V, Viale G, Mousa K, Palmieri C, Reed S, Nicholas H, et al.
Ann Oncol
. 2015 May;
26(9):1890-1897.
PMID: 26002610
Background: Intergroup Exemestane Study (IES) was a randomised study that showed a survival benefit of switching adjuvant endocrine therapy after 2-3 years from tamoxifen to exemestane. PathIES aimed to assess...
14.
Engels C, Charehbili A, van de Velde C, Bastiaannet E, Sajet A, Putter H, et al.
Breast Cancer Res Treat
. 2015 Jan;
149(3):587-96.
PMID: 25616355
Evidence exists for an immunomodulatory effect of endocrine therapy in hormone receptor-positive (HR+ve) breast cancer (BC). Therefore, the aim of this study was to define the prognostic and predictive value...
15.
Stephen J, Murray G, Cameron D, Thomas J, Kunkler I, Jack W, et al.
Br J Cancer
. 2014 Oct;
111(12):2242-7.
PMID: 25314051
Background: We investigated the impact of follow-up duration to determine whether two immunohistochemical prognostic panels, IHC4 and Mammostrat, provide information on the risk of early or late distant recurrence using...
16.
Ali H, Provenzano E, Dawson S, Blows F, Liu B, Shah M, et al.
Ann Oncol
. 2014 Jun;
25(8):1536-43.
PMID: 24915873
Background: T-cell infiltration in estrogen receptor (ER)-negative breast tumours has been associated with longer survival. To investigate this association and the potential of tumour T-cell infiltration as a prognostic and...
17.
Irshad S, Gillett C, Pinder S, AHern R, Dowsett M, Ellis I, et al.
Breast Cancer Res Treat
. 2014 Feb;
144(2):331-41.
PMID: 24519386
The TACT trial is the largest study assessing the benefit of taxanes as part of adjuvant therapy for early breast cancer. The goal of this translational study was to clarify...
18.
Bartlett J, Brookes C, Piper T, van de Velde C, Stocken D, Lyttle N, et al.
Br J Cancer
. 2013 Oct;
109(9):2453-61.
PMID: 24091623
Background: Epidermal growth factor receptors contribute to breast cancer relapse during endocrine therapy. Substitution of aromatase inhibitors (AIs) may improve outcomes in HER-positive cancers. Methods: Tissue microarrays were constructed. Quantitative...
19.
Shaaban A, Purdie C, Bartlett J, Stein R, Lane S, Francis A, et al.
J Clin Pathol
. 2013 Sep;
67(2):161-7.
PMID: 24062360
Human epidermal growth factor receptor 2 (HER2) testing is required for newly diagnosed breast cancer and advised for recurrent and metastatic breast cancer, to determine treatment planning using HER2-directed therapy...
20.
Aapro M, van de Velde C, Markopoulos C, Bartlett J, Putter H, Coleman R
Breast
. 2013 Mar;
22(4):488-94.
PMID: 23454040
Background: In the past few years aromatase inhibitors (AIs) have shown superior efficacy to the previous standard adjuvant endocrine therapy, tamoxifen, and are now recommended as part of current adjuvant...